Telomir Pharmaceuticals, Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $0.42
- 52-Week Range
- $0.40 – $1.58
- Market Cap
- $30.98M
- P/E (TTM)
- —
- EPS (TTM)
- -0.96
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 6.57
- PEG Ratio
- —
- Return on Equity
- -96.26%
- Return on Assets
- -59.01%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 19.61
- Debt/Equity
- 0.02
- Total Debt
- $68.76K
- Free Cash Flow
- $-2.88M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $26.53M
Market Snapshot
About
Telomir Pharmaceuticals, Inc. is a biotechnology company focused on developing therapeutics to extend healthspan by addressing cellular aging and age-related diseases. The company is researching compounds that may influence telomere biology and cellular senescence. Telomir aims to develop treatments for conditions associated with aging and metabolic dysfunction.